MedTrace Logo

Phase 2 Study of VGT-309 in Lung Cancer

NCT05400226 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-10-17

Study results available
· View outcomes & findings →

Summary

A Phase 2 open label study to evaluate safety and efficacy of VGT-309 to identify cancer in up to 40 subjects undergoing lung cancer surgery.

Conditions

Interventions

DRUG

VGT-309

VGT-309 is an tumor-targeted, activatable fluorescent imaging agent which will be used with near infrared imaging during surgery to identify tumor.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Vergent Bioscience, Inc.

    lead INDUSTRY

Principal Investigators

  • Curt Scribner, MD · Vergent Bioscience

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-24
Primary Completion
2023-06-24
Completion
2023-12-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05400226 on ClinicalTrials.gov